Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.590
+0.040 (2.58%)
Dec 20, 2024, 4:00 PM EST - Market closed
Regulus Therapeutics Employees
Regulus Therapeutics had 30 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
30
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,387,600
Market Cap
104.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Inotiv | 2,055 |
MDxHealth | 300 |
PetMed Express | 287 |
Champions Oncology | 210 |
X4 Pharmaceuticals | 93 |
Assembly Biosciences | 65 |
Genenta Science | 14 |
RGLS News
- 25 days ago - Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - PRNewsWire
- 6 weeks ago - Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 2 months ago - Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 4 months ago - Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - PRNewsWire
- 4 months ago - Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 4 months ago - Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire
- 6 months ago - Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 7 months ago - Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes - PRNewsWire